Search Results
Your search for ,Per matches 3772 pages
Showing 351 - 400First-Line Dabrafenib Plus Trametinib vs Standard Chemotherapy for Pediatric Low-Grade Glioma With BRAF V600 Mutations
As reported in The New England Journal of Medicine by Eric Bouffet, MD, of the Hospital for Sick Children, Toronto, and colleagues, a phase II trial has shown a significant improvement in objective response rate and other efficacy outcomes with first-line dabrafenib plus trametinib vs standard...
Studies Explore Efficacy of Venetoclax in t(11;14)-Positive Myeloma
In the global randomized phase III CANOVA study, venetoclax plus dexamethasone (VenDex) demonstrated numerically longer progression-free survival compared with pomalidomide and dexamethasone (PomDex) in patients with t(11;14)-positive relapsed or refractory multiple myeloma, though the difference...
Short-Course Radiotherapy May Reduce Resource Burden of Head and Neck Cancer Treatment in Low- and Middle-Income Countries
Resource-sparing hypofractionated radiation therapy could offer an invaluable alternative for treating head and neck cancer, especially for patients in low- and middle-income countries, according to data presented during the Plenary Session at the 2023 American Society for Radiation Oncology...
Expert Point of View: Solange Peters, MD, PhD and Upal Basu Roy, PhD, MPH
Commenting on the AEGEAN study at the 2023 World Conference on Lung Cancer were the abstract’s invited discussant Solange Peters, MD, PhD, Professor and Chair of Medical Oncology and the Thoracic Malignancies Program at Lausanne University Hospital in Switzerland, and Upal Basu Roy, PhD, MPH,...
Novel Assay May Help Detect and Treat Patients With AML
A novel assay may be effective at detecting a unique molecular marker in patients with acute myeloid leukemia (AML), according to a recent study published by Young et al in The Journal of Molecular Diagnostics. The new findings may revolutionize the way AML is detected and treated. Background AML...
Advancing Clinical Research on Ovarian Cancer and Overcoming Gender Inequity in Low- and Middle-Income Countries
The management of ovarian cancer remains challenging within health-care systems worldwide. Recently, clinical and translational research on ovarian cancer has led to promising advances that have improved the survival outcomes of women diagnosed with this aggressive gynecologic cancer. These...
Screening for Lung Cancer: Much Work Remains to Be Done
Remarkable progress has been made in the treatment of lung cancer in the past 10 to 15 years; it is therefore not surprising that lung cancer mortality in the United States is declining consistently, at the rate of 2% to 4% annually in recent years. Long-term survival is possible even for patients...
Results of PACIFIC Trial Being Replicated in Real-World Settings
Real-world outcomes often fall short of those achieved in clinical trials, but this is apparently not so for patients receiving chemoradiotherapy plus consolidation with durvalumab in unresectable stage III non–small cell lung cancer (NSCLC). The robust results achieved in the phase III PACIFIC...
Understanding Patient Engagement in Virtual Mind-Body Therapies
Guest Editor’s Note: Virtual platforms have grown increasingly popular for health- and wellness-promoting activities. But given patients’ unique backgrounds, capabilities, interests, and goals, promoting engagement represents a complex challenge both in the context of care delivery as well as...
Subsequent Cancer Diagnosis After No Diagnosis With Urgent Suspected Cancer Referral
In a national cohort study in England reported in The Lancet Oncology, Scott et al found a high rate of subsequent cancer diagnosis in persons with an urgent suspected cancer referral that did not result in cancer diagnosis. As noted by the investigators, “Following referral for investigation of...
Novel Strategy May Improve Outcomes in Patients With Treatment-Resistant DLBCL
Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of...
Addition of First-Line Pembrolizumab to Chemotherapy in HER2-Negative Advanced Gastric Cancer
As reported in The Lancet Oncology by Sun Young Rha, MD, and colleagues, the phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement in overall survival in patients with HER2-negative advanced...
ACS Releases Updated Lung Cancer Screening Guideline
Lung cancer incidence overall has been declining in the United States since 1992 and since 2006–2007 for both men and women by 2.7% annually and 1.1%, respectively, and overall mortality rates have declined in both men and women due to smoking cessation efforts and advances in therapy and early...
Expanded Soy Production in Brazil May Be Linked to Increased Mortality Among Pediatric Patients With ALL
Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased risk of mortality among pediatric patients with acute lymphoblastic leukemia (ALL). The study was published by Skidmore et al in...
Role of Crowdfunding Campaigns in Covering Medical Expenses for Cancer Survivors
Investigators have discovered that cancer survivors in the United States may be increasingly utilizing crowdfunding campaigns like GoFundMe to help cover the costs of medical and other basic household expenses, according to new findings presented by Zheng et al and Yu et al at the 2023 ASCO Quality ...
Intraductal Papillary Mucinous Neoplasms: Risk of Pancreatic Cancer
In a retrospective cohort study reported in JAMA Network Open, de la Fuente et al found that the risk of pancreatic cancer in patients with Fukuoka criteria–negative intraductal papillary mucinous neoplasms (F-N IPMNs) did not differ from that in patients without IPMNs. In addition, the small...
Perioperative Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer
A perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab achieved a statistically significant and clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant...
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
On October 27, the U.S. Food and Drug Administration (FDA) approved toripalimab-tpzi (Loqtorz) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for...
PFAS Exposure May Increase Risk of Thyroid Cancer
Researchers may have discovered a link between certain per- and polyfluoroalkyl substances (PFAS)—also referred to as "forever chemicals"—and an increased risk of thyroid cancer, according to a recent study published by van Gerwen et al in eBioMedicine. Background PFAS are a large, complex group of ...
Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy
Researchers have found that a text message–based program in combination with routine laboratory testing could safely accelerate patients to treatment with immune checkpoint inhibitors, eliminate the need for in-person assessments with their physicians, and save them about 1.5 hours in total wait...
Mind-Body Fitness Classes May Reduce Unplanned Hospitalizations, Urgent Care Visits During Cancer Care
Participation in virtual mind-body fitness classes may be effective at reducing hospitalizations, urgent care visits, and the length of hospital stays among patients with cancer by about 50%, according to new findings presented by Mao et al at the 2023 ASCO Quality Care Symposium (Abstract 473)....
Role of TROP-2–Directed Antibody-Drug Conjugates With Immune Checkpoint Inhibitors in Advanced NSCLC
Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...
From Humble Beginnings, Elisabete Weiderpass, MD, MSc, PhD, Distinguishes Herself as First Woman to Head the IARC
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Elisabete Weiderpass, MD, MSc, PhD, a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In...
Patient Education Materials on Breast Cancer May Be Difficult to Access
Investigators have discovered that reliable educational materials about breast cancer surgery may be difficult to access and are often presented at much higher reading levels than recommended, according to the findings of two new studies presented by Brennan et al and Satarasinghe et al at the...
Trends in Lung Cancer Incidence Among Women and Men in the United States
In a study reported in a research letter in JAMA Oncology, Jemal et al found that rates of lung cancer declined more in men vs women in the United States in recent years, such that incidence is now higher in women vs men aged ≤ 55 years. As stated by the investigators, “A previous study from the...
Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial
The Alliance for Clinical Trials in Oncology announced detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors. The data were presented by Chan et al at the...
EVEREST Trial: Adjuvant Everolimus for High-Risk Clear Cell Renal Cell Carcinoma
A secondary analysis from the phase III SWOG S0931 EVEREST trial found patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectomy who received adjuvant everolimus had a statistically significant improvement in recurrence-free survival compared to patients who...
FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for Resectable NSCLC
On October 16, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as postsurgical adjuvant treatment, for resectable (tumors ≥ 4 cm or node-positive)...
How War Has Disrupted the Management of Patients With Breast Cancer in Sudan
Sudan is the third-largest country in Africa, spanning 1,886,068 km2. It is situated in an area surrounded by North Africa, Sub-Saharan Africa, and the Middle East. As of 2020, Sudan had a population of approximately 43.8 million people, with a significant proportion being younger than age 15....
Chemical Hair Relaxers May Increase Risk of Uterine Cancer Among Black Women
Researchers have found that long-term use of chemical hair relaxers may be associated with an increased risk of uterine cancer in postmenopausal Black women, according to a recent study published by Bertrand et al in Environmental Research. Background Chemical hair relaxers are heavily marketed to...
Nonmelanoma Skin Cancers May Have Higher Mortality Rate Than Melanoma
Nonmelanoma skin cancer may be causing a greater number of global deaths than melanoma, according to findings presented by Salah et al at the European Academy of Dermatology and Venerology Congress 2023. Investigators also suggested that nonmelanoma skin cancer may be underreported and that the...
FDA Approves Encorafenib With Binimetinib for Metastatic BRAF V600E–Mutated NSCLC
On October 11, the U.S. Food and Drug Administration (FDA) approved the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) for adult patients with metastatic non–small cell lung cancer (NSCLC) and a BRAF V600E mutation, as detected by an FDA-approved test. The FDA...
Patterns in Early-Onset Cancer in the United States From 2010 to 2019
In a study using SEER (Surveillance, Epidemiology, and End Results) registry data reported in JAMA Network Open, Daniel Q. Huang, MBBS, MMED, of the National University of Singapore, and colleagues found that the incidence of cancer among U.S. persons up to age 50 (early-onset cancer) increased...
Melphalan-Based Liver-Directed Therapy for Metastatic Uveal Melanoma
On August 14, 2023, the Hepzato Kit—melphalan for injection/hepatic delivery system—was approved as a liver-directed treatment for adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver.1 Patients must have either no extrahepatic disease or extrahepatic ...
NUC-1031/Cisplatin Fails to Improve Outcomes in Advanced Biliary Tract Cancer
As a first-line treatment for advanced biliary tract cancer, an experimental formulation of gemcitabine, NUC-1031, given with cisplatin failed to improve outcomes over standard gemcitabine/cisplatin in the global phase III NuTide:121 trial.1 “NuTide:121 has not advanced the field in biliary tract...
Individualized SABR for Lung Tumors
In a phase II study (iSABR) reported in JAMA Oncology, Gensheimer et al found that individualized stereotactic ablative radiotherapy (SABR) for up to four lung cancer tumors was associated with a high degree of local control and the ability to minimize radiation doses. Study Details Two hundred and ...
Structural Racism’s Effect on Cancer Mortality Rates
Racial minority patients are impacted differently by the social and physical characteristics of their environments, which may negatively affect cancer outcomes compared with White patients with cancer, according to a new study by Robinson-Oghogho et al presented during the 16th AACR Conference on...
Hypofractionated Radiotherapy May Reduce Burden of Head and Neck Cancer in Low- and Middle-Income Countries
Fewer and higher doses of radiation may be effective at treating patients with head and neck squamous cell carcinoma, according to new findings presented by Bentzen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 02). Background Head and neck squamous...
Unconscious Gender Biases and Discrimination Lead to Suboptimal Care for Women
Gender inequalities and discrimination may adversely impact women’s rights and opportunities to avoid cancer risk factors and impede their ability to seek and obtain timely diagnoses and quality cancer care, according to The Lancet Commission on Women, Power, and Cancer published by Ginsburg et al...
Using Whole-Body Imaging Agent to Predict Response to Treatment in HER2-Positive Metastatic Breast Cancer
The novel imaging agent gallium (Ga)-68–ABY-025 may help to predict early metabolic response to HER2-targeted treatment in patients with HER2-positive metastatic breast cancer, according to a recent study published by Alhuseinalkhudhur et al in The Journal of Nuclear Medicine. These findings...
Management of Stage I Breast Cancer
This is Part 1 of Ovarian Function Suppression in Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jame Abraham, Erin Roesch, and Azka Ali discuss the management of stage I breast cancer. The patient is a...
High-Intensity Training May Reduce the Risk of Colorectal Cancer in Patients With Lynch Syndrome
Regular and intense aerobic exercise may be effective at reducing the risk of colorectal cancer in patients with Lynch syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to a novel study published by Deng et al in Clinical Cancer Research....
Exposure to PFAS and Phenols May Be Linked to Cancer Risk
Investigators have discovered that significantly higher levels of endocrine-disrupting chemicals such as per- and poly-fluoroalkyl substances (PFAS) and phenols may be present in patients with breast, ovarian, skin, and endometrial cancers, according to a recent study published by Cathey et al in...
Surgical Oncologist Héber Salvador, MD, PhD, Offers an Inside Look at Cancer Care in Brazil, Complete With Its Diversity and Inequities
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha, spoke with Héber Salvador, MD, PhD,...
Accelerating Progress Against Cancer and Other Life-Threatening Diseases
Cancer—and the quest to accelerate more effective treatments and potential cures for all life-threatening diseases—has perhaps shaped the life of financier Michael Milken more than his legendary career on Wall Street. In the early 1970s, Mr. Milken’s mother-in-law was diagnosed with metastatic...
The Immune System May Play Vital Role in Remission Duration Among Patients With Multiple Myeloma
Researchers have uncovered the vital role that the immune system may play in determining the duration of remission and progression-free survival in patients with multiple myeloma, according to a recent study published by Coffey et al in Nature Communications. The new findings suggested that the...
LungCAN Advocacy Program Nets 25% Increase in LCRP Funding
The Lung Cancer Action Network (LungCAN) advocacy program may have helped increase funding for the U.S. Department of Defense Congressionally Directed Medical Research Program/Lung Cancer Research Program (LCRP) by 25%, according to recent findings presented by Donaldson et al at the International...
NSCLC: Osimertinib Plus Chemo vs Osimertinib Alone
Osimertinib plus chemotherapy may have demonstrated a statistically significant and clinically meaningful progression-free survival benefit in patients with advanced non–small cell lung cancer (NSCLC) compared with osimertinib alone, according to new findings presented by Jänne et al at the...
Study Shows Exercise May Improve Sexual Function in Men With Prostate Cancer
It seems that exercise is good for almost everything, including prostate cancer. In fact, exercise had a positive effect on sexual function and enjoyment in men with prostate cancer, according to a recent study presented at the 2023 ASCO Breakthrough meeting by lead study author Daniel Galvão, PhD, ...
There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
